| Literature DB >> 34056633 |
Xue-Quan Zhou1, Imma Carbo-Bague1,2, Maxime A Siegler3, Jonathan Hilgendorf1, Uttara Basu4, Ingo Ott4, Rongfang Liu5, Liyan Zhang1, Vadde Ramu1, Adriaan P IJzerman5, Sylvestre Bonnet1.
Abstract
In this work, a pair ofEntities:
Year: 2021 PMID: 34056633 PMCID: PMC8154207 DOI: 10.1021/jacsau.0c00104
Source DB: PubMed Journal: JACS Au ISSN: 2691-3704
Scheme 1(a) Scheme for rollover cyclometalation. Adapted from ref (40). Copyright 2015 American Chemical Society. “B” represents a base. (b) Synthesis of the gold complexes [1]Cl and [2]Cl.
Figure 1(a) Cationic part and ring numbers (red characters) in the crystal structures (wireframe style) of gold complexes [1]Cl and [2](AuCl4). The counterions were omitted for clarity. (b) Selected angles (deg) and distances (Å) in [1]Cl and [2](AuCl4). The least-squares plane defined by the rings D and F is shown as a red line. For [1]Cl, only one of the three crystallographically independent cations is shown in (a) and (b). (c) Space fill construction and schematic pictures of the supramolecular helixes in the crystal structure of [1]Cl and [2](AuCl4). The Au atoms are labeled in yellow, Cl in pink, coordinated N in pale blue, coordinated C in gray, and noncoordinated C in green, dark blue, and red.
Figure 2Structure, calculated geometry, and frontier orbitals (HOMO, LUMO) of (a) [1]+ and [1a]+, (b) [2]+ and [2a]+. (c) Proposed mechanism for the C–H activation and cyclometalation of H2biqbpy1 to form [1]Cl.
Calculated Information of Complexes [1]+, [2]+, [1a]+ and [2a]+
| complex | HOMO | LUMO | Δ | relative total bind energy (eV) | end ring π–π distance (Å) |
|---|---|---|---|---|---|
| [1]+ | –6.028 | –2.520 | 3.508 | 0 | 4.55 |
| [2]+ | –6.118 | –3.267 | 2.851 | +0.8790 | 4.06 |
| [1a]+ | –5.707 | –3.096 | 2.611 | +0.7726 | 6.70 |
| [2a]+ | –6.332 | –2.586 | 3.746 | –0.6004 | 7.29 |
Figure 3(a) Time evolution of the absorbance spectrum of [1]Cl and [2]Cl (50 μM) in PBS solution containing GSH (100 μM) for 25 min: Measurement interval, 12 s; color changes from black (0 s) to red (25 min). (b) 1H NRM monitoring of a [2]Cl/GSH mixture in D2O (concentration ratio 3 mM/6 mM). Orange circle and green triangle indicate different Au(I) species. (c) Time evolution of the absorbance spectrum of [1]Cl and [2]Cl (50 μM) in Opti-MEM medium solution containing FCS (2.5% v/v) for 24 h. Measurement interval, first 30 min every 0.5 min, the left 23.5 h every 15 min; color changes from black (0 s) to red (25 min). (d) DLS size distribution and derived count rate of [1]Cl and [2]Cl (50 μM) in Opti-MEM medium solution containing FCS (2.5% v/v).
Half-Maximal Effective Concentrations (EC50 in μM) of Gold Complexes [1]Cl and [2]Cl and Cisplatin toward 2D Cancer Cell and Healthy Cell Monolayers in Normoxic (21% O2) and Hypoxic (1% O2) Conditionsa
| EC50 (μM) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| complex | A549 | ±CI | A431 | ±CI | A375 | ±CI | MCF7 | ±CI | MRC5 | ±CI | A549-3D | ±CI | |
| [1]Cl2 | normoxic | 3.3 | +0.7, −0.6 | 4 | +1, −1 | 5 | +1, −1 | 4 | +1, −1 | 27 | +16, −9 | 7 | +4, −2 |
| hypoxic | 5 | +2, −2 | 16 | +7, −5 | 6 | +3, −2 | 9 | +2, −1 | 28 | +9, −6 | ND | ||
| [2]Cl | normoxic | 3.1 | +0.3, −0.3 | 3.5 | +0.6, −0.5 | 0.7 | +0.2, −0.1 | 0.3 | +0.1, −0.1 | 3.3 | +0.8, −0.7 | 4 | +3, −2 |
| hypoxic | 3.9 | +0.7, −0.6 | 2.9 | +0.8, −0.5 | 4 | +4, −2 | 2.1 | +0.1, −0.1 | 1.5 | +0.2, −0.2 | ND | ||
| cisplatin | normoxic | 4.5 | +0.7, −0.6 | 1.8 | +0.5, −0.4 | 1.2 | +0.1, −0.1 | 3.6 | +1.2, −0.9 | 5.8 | +1.5, −1.2 | 0.8 | +0.3, −0.2 |
| hypoxic | 24 | +11, −5 | 13 | +4, −3 | 3.4 | +0.8, −0.7 | ND | 9.4 | +5.7, −3.6 | ND | |||
95% confidence interval values (CI in μM over three independent biological experiments) are also indicated. ND: not determined.
Figure 4(a) Flow cytometry quantification of healthy, early apoptotic, later apoptotic, and necrotic A549 cells after treatment with cisplatin (15 μM), [1]Cl (10 μM), or [2] Cl (10 μM) for 24 h. (b) Au content (ICP-MS) of A549 cells after treatment with [1]Cl or [2]Cl (1 μM) for 24 h. (c) Intracellular Au content (according to ICP-MS) for A549 cells treated with [1]Cl or [2]Cl (5 μM) for 2 h at 4 or 37 °C. (d) EC50 values for [1]Cl, [2]Cl, or cisplatin in 3D multicellular tumor spheroids of A549 cells, based on a 3D CellTiterGlo ATP end-point assay.
Binding of Tetrapyridyl Ligands and Their Au(III) Complexes to TrxR and Kv11.1 Proteins
| compd | TrxR inhibition IC50 (μM) | [3H]dofetilide binding remaining (%) | Kv11.1 binding (%) |
|---|---|---|---|
| H2biqbpy1 | ND | 64 ± 4 | 36 ± 4 |
| [1]Cl | >5 | 8.7 ± 0.1 | 91.3 ± 0.1 |
| H2biqbpy2 | ND | 16 ± 4 | 84 ± 4 |
| [2]Cl | 0.13 ± 0.02 | 7.9 ± 0.2 | 92.1 ± 0.2 |
ND = not determined.
tested concentration = 10 μM.
Kv11.1 binding (%) = 100%-[3H]dofetilide binding remaining (%).